Screener
Polaryx Therapeutics, Inc. PLYX Preferred Stock Par Value Per Share
Preferred Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The source filing: Polaryx Therapeutics, Inc.’s 10-K, filed March 24, 2026.
- Filed
- Mar 24, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001213900-26-033064
| Line item | As of / December 31, 2025 | As of / December 31, 2024 |
|---|---|---|
| Total liabilities | 605 | 289 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.0001 par value, 40,000,000 shares authorized; 0 and 0 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — |
| Common stock: $0.0001 par value; 560,000,000 shares authorized; 47,343,297 and 41,151,571 shares issued and outstanding at December 31, 2025 and 2024, respectively | 5 | 4 |
| Additional paid-in capital | 104,195 | 95,358 |
| Accumulated deficit | (99,635) | (90,650) |
| Total stockholders’ equity | 4,565 | 4,712 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Polaryx Therapeutics, Inc.'s preferred stock par value per share?
- Polaryx Therapeutics, Inc. (PLYX) reported preferred stock par value per share of $0.00 in Q4 2025.
- What does preferred stock par value per share mean?
- The par value per share of preferred stock is a nominal value assigned to preferred shares for accounting and legal purposes. It does not reflect the market value or the liquidation preference of the stock. It is primarily a regulatory and historical accounting figure.
Ask your AI about Polaryx Therapeutics, Inc.'s preferred stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude